SCHEMBL4355343

SCHEMBL4355343

O=C(O)c1csc(-c2cccc(Cl)c2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.64
ALDH1A1 P00352 3/20 0.64
L3MBTL1 Q9Y468 3/20 0.64
MAPT P10636 3/20 0.64
ATM Q13315 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
KDM4E B2RXH2 2/20 0.64
MEN1 O00255 1/20 0.64
LMNA P02545 1/20 0.64
GAA P10253 1/20 0.64
HPGD P15428 1/20 0.64
KMT2A Q03164 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
HPGDS O60760 1/20 0.57
LDHA P00338 1/20 0.56
ADRB2 P07550 2/20 0.55
ADRB1 P08588 2/20 0.55
ADRB3 P13945 2/20 0.55
TDP1 Q9NUW8 2/20 0.53
NPY1R P25929 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3057919 0.88 TLR7 (0.64) TLR7ALDH1A1L3MBTL1MAPTATM
SCHEMBL2555429 0.83 TLR7 (0.70) TLR7ALDH1A1L3MBTL1MAPTATM
SCHEMBL352152 0.82 HPGDS (0.73) TLR7ALDH1A1L3MBTL1MAPTATM
SCHEMBL6182649 0.82 HPGDS (0.57) ALDH1A1KDM4EHPGDSTDP1PLA2G10
SCHEMBL3353616 0.82 ALDH1A1 (0.68) ALDH1A1KDM4EHPGDSKMOPLA2G10
SCHEMBL31351171 0.82 KDM4E (0.66) TLR7ALDH1A1KDM4ELMNASMN1; SMN2
SCHEMBL2551944 0.82 TLR7 (0.63) TLR7ALDH1A1KDM4EHPGDSTDP1
SCHEMBL3412110 0.81 ALDH1A1 (0.71) TLR7ALDH1A1L3MBTL1MAPTATM
Hydrochloric Acid SCHEMBL6821751 0.80 HPGDS (0.71) TLR7ALDH1A1L3MBTL1MAPTATM
SCHEMBL12171802 0.80 CYP19A1 (0.67) ALDH1A1L3MBTL1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202772-A1 COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2022-06-30 US disclosed
EP-2070916-A1 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202772-A1 COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS RACK1, RRBP1, RPL30 TLR7 4701/4885ALDH1A1 3524/4885L3MBTL1 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.